Rani Therapeutics Holdings (RANI): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand ranitherapeutics.com (RANI)

Unique patents for robotic biologic delivery create a powerful technological barrier for Rani Therapeutics (RANI). This price-to-sales chart demonstrates current volatility, where the 9.50 mark captures this metric. The asset's stability currently depends on clinical test results, yet the scaling potential of RaniPill promises high margins due to low-cost automated capsule production.

Price-to-Revenue Ratio: Rani Therapeutics Inc (RANI) for 07/04/2022 - 11/14/2026

Rani Therapeutics (RANI) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart ranitherapeutics.com|RANI - Price Target Chart
- stock exchange capitalization data:
Market Value Rani Therapeutics Inc|RANI - Enterprise Value
- book capitalization indicators:
Book Value per Share Rani Therapeutics|RANI - Company Book Value|Capitalization to Book Value Ratio ranitherapeutics.com|RANI - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Rani Therapeutics|RANI - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ranitherapeutics.com|RANI - Company Total Debt|Debt to Book Capital Rani Therapeutics Inc|RANI - Company Long-Term Debts|Company Short-Term Loans and Borrowings Rani Therapeutics|Immediate Liquidity ranitherapeutics.com
- company profitability and valuation multiples indicators:
RANI - Company Net Income|Expected Net Income Rani Therapeutics|RANI - P/E Multiple|Forward P/E Multiple ranitherapeutics.com|RANI - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Rani Therapeutics Inc|RANI - Operating profit EBITDA|Net earnings per one share for the last twelve months Rani Therapeutics|RANI - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ranitherapeutics.com|RANI - Net earnings per share growth this year|Projected earnings per share increase next year Rani Therapeutics
- total revenue and sales volume data:
RANI - Revenue and Sales Volume|Company Future Sales ranitherapeutics.com|RANI - P/S Multiple|Forward Price-to-Revenue Multiple Rani Therapeutics Inc
Summary company analytics:Rani Therapeutics Holdings
Core merchandise of Rani Therapeutics Holdings, Inc.

Rani Therapeutics (RANI) focuses on clinical trials of robotic capsules and currently generates no commercial revenue. Due to the absence of sales, the estimated price-to-sales ratio tends toward infinity, reflecting a speculative valuation of future successes. This metric compares the business's market value with its sales volume to determine the asset's premium. Analysis based on the estimated price-to-sales ratio allows for the timely detection of a dangerous gap between capitalization and actual cash flows.

Competing companies

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|Market Capitalization-to-Revenue Ratio VRNA|Jyong Biotech Corp - P/S Multiple|LGND - P/S Multiple|Amneal Pharmaceuticals (AMRX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PRGO|ALVO (Alvotech SA) - P/S Multiple|Liquidia Corp (LQDA) - Price-to-Revenue Coefficient|Market Cap to Revenue GLPG (Galapagos Genomics)|ANIP (ANI Pharmaceuticals Corp) - Market Capitalization-to-Revenue Ratio|MannKind Corporation - Market Cap to Revenue|Market Cap to Sales Volume AMPH (amphastar.com)|Pacira BioSciences, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio SPRY (ARS Pharmaceuticals Inc)|TBPH: P/S Multiple|Price to Sales Aquestive Corp (AQST)|Price-to-Revenue Ratio scPharmaceuticals, Inc.|TECX: Market Capitalization-to-Revenue Ratio|P/S Multiple TNXP|P/S Multiple sxtchina.com (SXTC)|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|BHST (BioHarvest Sciences Inc) - Price-to-Sales Ratio|eXoZymes Inc - P/S Multiple|Price to Sales Oramed Pharmaceuticals|ENTX (enterabio.com) - Market Cap to Revenue|MindWalk Holdings, Inc. (HYFT) - P/S Multiple|Market Cap to Revenue ABVC|CPIX (Cumberland Corp) - Market Cap to Sales Volume|P/S Multiple QNTM|Price-to-Revenue Coefficient fibrogen.com|P/S Multiple TELO (Telomir Pharmaceuticals, Inc.)|SNYR - Market Cap to Revenue|RLYB - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Lexaria Bioscience LEXX|Pulmatrix, Inc. (PULM) - Price-to-Revenue Ratio|Pheton Holdings - Market Capitalization-to-Revenue Ratio|APM (Aptorum Group Ltd) - P/S Multiple|P/S Multiple Lyra Therapeutics Inc.|Price-to-Revenue Ratio Impact BioMedical (IBO)|tnfpharma.com - Market Cap to Revenue Ratio|P/S Multiple YCBD (cbdMD)|Price-to-Revenue Coefficient painreform.com (PRFX)|CYTO - Price-to-Revenue Ratio|Price-to-Sales Ratio LIPO|OPTN: P/S Multiple|Pieris Pharma - Market Capitalization-to-Revenue Ratio|PROC (Procaps Group S.A.) - P/S Multiple|P/S Multiple petrospharma.com|Price-to-Revenue Ratio Qilian International Holding (QLI)|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TFF Pharma TFFP